Vivos Therapeutics is trying to grow its sleep-related treatments, but heavy debt, ongoing losses, and tighter access to financing could force painful fundraising and slow expansion. At the same time, shifting patient spending, insurance and regulatory hurdles, and well-known alternatives like CPAP could make it harder to win and keep share.Read more
A medical device company is getting regulatory green lights and riding growing demand for gentler sleep apnea treatment, which could open the door to more patients beyond the usual mask-based approach. The catch is it’s still burning cash and betting on rapid clinic rollouts and insurance coverage to replace fading legacy sales before financing costs and competition bite.Read more
Key Takeaways Surging patient demand and rapid operational rollout support potential for significantly higher revenue, margin expansion, and accelerated positive cash flow beyond current expectations. Clinically validated solutions, experienced leadership, and streamlined workflows position the company for rapid, scalable growth and sustained, high-margin recurring revenue.Read more
No trending discussion available.
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
